Last reviewed · How we verify
mRNA
mRNA-based therapeutics deliver genetic instructions to cells to produce therapeutic proteins or trigger immune responses.
mRNA-based therapeutics deliver genetic instructions to cells to produce therapeutic proteins or trigger immune responses. Used for Personalized cancer vaccines (investigational), Infectious disease vaccines (investigational).
At a glance
| Generic name | mRNA |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Drug class | mRNA therapeutic |
| Modality | Biologic |
| Therapeutic area | Oncology, Immunology, Infectious Disease, Genetic Disorders |
| Phase | FDA-approved |
Mechanism of action
mRNA drugs encode instructions for cells to synthesize specific proteins that either replace deficient proteins, provide enzymatic function, or stimulate the immune system to recognize and attack disease targets. The mRNA is typically encapsulated in lipid nanoparticles for cellular delivery and translation into functional proteins.
Approved indications
- Personalized cancer vaccines (investigational)
- Infectious disease vaccines (investigational)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
- Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism (EARLY_PHASE1)
- A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection (PHASE1, PHASE2)
- Target of Suv420h1/2 in Hepatocytes (NA)
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA CI brief — competitive landscape report
- mRNA updates RSS · CI watch RSS
- University Hospital Tuebingen portfolio CI